Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients
NCT04695470
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
70
Enrollment
UNKNOWN
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Fruquintinib and Sintilimab
Sponsor
Aiping Zhou